These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36074578)

  • 1. The druggable transcription factor Fli-1 regulates T cell immunity and tolerance in graft-versus-host disease.
    Schutt SD; Wu Y; Kharel A; Bastian D; Choi HJ; Hanief Sofi M; Mealer C; McDaniel Mims B; Nguyen H; Liu C; Helke K; Cui W; Zhang X; Ben-David Y; Yu XZ
    J Clin Invest; 2022 Nov; 132(21):. PubMed ID: 36074578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice.
    Wu Y; Bastian D; Schutt S; Nguyen H; Fu J; Heinrichs J; Xia C; Yu XZ
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1195-204. PubMed ID: 25846718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
    Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
    Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
    Yao Y; Wang L; Zhou J; Zhang X
    J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway.
    Sofi MH; Tian L; Schutt S; Khan I; Choi HJ; Wu Y; Bastian D; Ticer T; Kassir MF; Atilgan FC; Kim J; Sui X; Zivkovic A; Mehrotra S; O'Bryan JP; Stark H; Martin PJ; Ogretmen B; Yu XZ
    Leukemia; 2022 Jul; 36(7):1907-1915. PubMed ID: 35513703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
    Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
    Front Immunol; 2020; 11():593863. PubMed ID: 33324410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
    Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
    Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
    van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
    Front Immunol; 2020; 11():1804. PubMed ID: 32973756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S1P/S1PR1 signaling differentially regulates the allogeneic response of CD4 and CD8 T cells by modulating mitochondrial fission.
    Tian L; Wu Y; Choi HJ; Sui X; Li X; Sofi MH; Kassir MF; Chen X; Mehrotra S; Ogretmen B; Yu XZ
    Cell Mol Immunol; 2022 Nov; 19(11):1235-1250. PubMed ID: 36071219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity.
    Betts BC; Locke FL; Sagatys EM; Pidala J; Walton K; Menges M; Reff J; Saha A; Djeu JY; Kiluk JV; Lee MC; Kim J; Kang CW; Tang CH; Frieling J; Lynch CC; List A; Rodriguez PC; Blazar BR; Conejo-Garcia JR; Del Valle JR; Hu CC; Anasetti C
    Front Immunol; 2018; 9():2887. PubMed ID: 30574153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relationship between WT1-specific T-cell subsets and graft-versus-host disease after nonmyeloablative allogeneic transplantation].
    Wei L; Zuo HL; Liu TQ; Sun XD; Guo M; Liu GX; Sun QY; Qiao JH; Wang DH; Yu CL; Hu KX; Dong Z; Ai HS
    Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):89-93. PubMed ID: 21429373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.
    Matte-Martone C; Liu J; Jain D; McNiff J; Shlomchik WD
    Blood; 2008 Apr; 111(7):3884-92. PubMed ID: 18223170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects.
    Sykes M; Harty MW; Szot GL; Pearson DA
    Blood; 1994 May; 83(9):2560-9. PubMed ID: 7909457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.
    Weisdorf D; Zhang MJ; Arora M; Horowitz MM; Rizzo JD; Eapen M
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1727-33. PubMed ID: 22766220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.